Novel estrogen receptor coregulators and signaling molecules in human diseases

Cellular and Molecular Life Sciences

Volumn 61, Issue 3, 2004, Pages 281-291

  Barnes, C J ^a   Vadlamudi, R K ^a   Kumar, R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Chromatin remodeling; Coregulators; Estrogen receptor; Signaling pathways

Indexed keywords

ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR 1; CELL NUCLEUS RECEPTOR; CONJUGATED ESTROGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; E6 ASSOCIATED PROTEIN; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; HISTONE; HISTONE ACETYLTRANSFERASE PCAF; HYPOXIA INDUCIBLE FACTOR 1; MEDROXYPROGESTERONE ACETATE; METASTASIS ASSOCIATED PROTEIN 1; METASTASIS ASSOCIATED PROTEIN 1 INTERACTING COACTIVATOR; MODULATOR OF NONGENOMIC ACTION OF ESTROGEN RECEPTOR; NUCLEAR RECEPTOR COACTIVATOR 2; P21 ACTIVATED KINASE 1; PROLINE GLUTAMIC ACID LEUCINE RICH PROTEIN 1; PROTEIN P160; PROTEIN P300; PROTEIN PGC1; PROTEIN SNF2; RALOXIFENE; REGULATOR PROTEIN; RESVERATROL; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BIOLOGY; BONE METABOLISM; BRAIN INJURY; CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CHROMATIN STRUCTURE; CLINICAL TRIAL; DEMENTIA; ENDOMETRIUM CANCER; ENHANCER REGION; ESTROGEN ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; ESTROGEN THERAPY; GENE REPRESSION; HEART PROTECTION; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; LIGAND BINDING; NEUROPROTECTION; OSTEOPOROSIS; PATHOPHYSIOLOGY; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STROKE; TRANSCRIPTION REGULATION; VASODILATATION;

BONE AND BONES; CARDIOVASCULAR PHYSIOLOGY; CHROMATIN; ESTROGENS; HUMANS; NEOPLASMS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; RECEPTORS, ESTROGEN; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION;

EID: 1242351785     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-003-3222-5     Document Type: Review

References (112)

1. McDonnell D. P. and Norris J. D. (2002) Connections and regulation of the human estrogen receptor. Science 296: 1642-1644
2. Couse J. F. and Korach K. S. (1999) Estrogen receptor null mice: what have we learned and where will they lead us? Endocrinol. Rev. 20: 358-417
3. Poola I., Abraham J. and Baldwin K. (2002) Identification of ten exon deleted ERbeta mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor beta mRNA is distinct from that of estrogen receptor alpha. FEBS Lett. 516: 133-138
4. Nilsson S., Makela S., Treuter E., Tujague M., Thomsen J., Andersson G. et al. (2001) Mechanisms of estrogen action. Physiol. Rev. 81: 1535-1565
5. Kumar V., Green S., Stack G., Berry M., Jin J. R. and Chambon P. (1987) Functional domains of the human estrogen receptor. Cell 51: 941-951
6. MacGregor Schafer J., Liu H., Bentrem D. J., Zapf J. W. and Jordan V. C. (2000) Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res. 60: 5097-5105
7. Liu H., Park W.-C., Bentrem D. J., McKian K. P., De los Reyes A., Loweth J. A. et al. (2002) Structure-function relationships of the raloxifene-estrogen receptor-complex for regulating transforming growth factor expression in breast cancer cells. J. Biol. Chem. 277: 9189-9198
8. Berry M., Metzger D. and Chambon P. (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9: 2811-2818
9. Levin E. R. (2003) Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol. Endocrinol. 17: 309-317
10. Dubik D. and Shiu R. P. (1988) Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J. Biol. Chem. 263: 12705-12708
11. McKenna N. J., Lanz R. B. and O'Malley B. W. (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 20: 321-344
12. Webb P., Nguyen P., Shinsako J., Anderson C., Feng W., Nguyen M. P. et al. (1998) Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol. Endocrinol. 12: 1605-1618
13. Onate S. A., Boonyaratanakornkit V., Spencer T. E., Tsai S. Y., Tsai M. J., Eswards D. P. et al. (1998) The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J. Biol. Chem. 273: 12101-12108
14. Enmark E., Pelto H., Grandien K., Lagercrantz S., Lagercrantz J., Fried G. et al. (1997) Human estrogen receptor beta-gene structure, chromosomal localization and expression pattern. J. Clin. Endocrinol. Metab. 82: 4258-4265
15. Hall J. M., Couse J. F. and Korach K. S. (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 276: 36869-36872
16. Collingwood T. N., Urnov F D. and Wolffe A. P. (1999) Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J. Mol. Endocrinol. 23: 255-275
17. Kushner P. J., Agard D. A., Greene G. L., Scanlan T. S., Shiau A. K., Uht R. M. et al. (2000) Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74: 311-317
18. Saville B., Wormke M., Wang F., Nguyen T., Enmark E., Kuiper G. et al. (2000) Ligand-, cell- and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J. Biol. Chem. 275: 5379-5387
19. Landers J. P. and Spelsberg T. C. (1992) New concepts in steroid hormone action: transcription factors, proto-oncogenes and the cascade model for steroid regulation of gene expression. Crit. Rev. Euk. Gene Expr. 2: 19-63
20. Schiff R., Massarweh S., Shou J. and Osborne C. K. (2003) Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 9: 447S-454S
21. Wong C. W., McNally C., Nickbarg E., Komm B. S. and Cheskis B. J. (2002) Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc. Natl. Acad. Sci. USA 99: 14783-14788
22. Doolan C. M. and Harvey B. J. (2003) A Galphas protein-coupled membrane receptor, distinct from the classical oestrogen receptor, transduces rapid effects of oestradiol on [Ca(2+)](i) in female rat distal colon. Mol. Cell Endocrinol. 199: 87-103
23. Lee A. V., Cui X. and Oesterreich S. (2001) Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin. Cancer Res. 7: 4429S-4435S
24. McKenna N. J., Lanz R. B. and O'Malley B. W. (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 20: 321-344
25. Glass C. K., Rose D. W. and Rosenfeld M. G. (1997) Nuclear receptor coactivators. Curr. Opinion Cell. Biol. 9: 222-232
26. Ma H., Hong H., Huang S. M., Irvine R. A., Webb P., Kushner P. J. et al. (1999) Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol. Cell Biol. 19: 6164-6173
27. Heery D. M., Kalkhoven E., Hoare S. and Parker M. G. (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387: 733-736
28. Chang C., Norris J. D., Gron H., Paige L. A., Hamilton P. T., Kenan D. J. et al. (1999) Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol. Cell Biol. 19: 8226-8239
29. Cohen R. N., Brzostek S., Kim B., Chorev M., Wondisford F. E. and Hollenberg A. N. (2001) The specificity of interactions between nuclear hormone receptors and corepressors is mediated by distinct amino acid sequences within the interacting domains. Mol. Endocrinol. 15: 1049-1061
30. Webb P., Nguyen P. and Kushner P. J. (2003) Differential SERM effects on corepressor binding dictate ERalpha activity in vivo. J. Biol. Chem. 278: 6912-6920
31. Torchia J., Glass C. and Rosenfeld M. G. (1998) Co-activators and co-repressors in the integration of transcriptional responses. Curr. Opin. Cell Biol. 10: 373-383
32. Spencer T. E., Jenster G., Burcin M. M., Allis C. D., Zhou J., Mizzen C. A. et al. (1997) Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389: 194-198
33. Chakravarti D., LaMorte V. J., Nelson M. C., Nakajima T., Schulman I. G., Juguilon H. et al. (1996) Role of CBP/P300 in nuclear receptor signalling. Nature 383: 99-103
34. Chen D., Ma H., Hong H., Koh S. S., Huang S. M., Schurter B. T. et al. (1999) Regulation of transcription by a protein methyltransferase. Science 284: 2174-2177
35. Chen D., Huang S. M. and Stallcup M. R. (2000) Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300. J. Biol. Chem. 275: 40810-40816
36. Fryer C. J. and Archer T. K. (1998) Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. Nature 393: 88-91
37. Yoshinaga S. K., Peterson C. L., Herskowitz I. and Yamamoto K. R. (1992) Roles of SWI1, SWI2 and SWI3 proteins for transcriptional enhancement by steroid receptors. Science 258: 1598-1604
38. DiRenzo J, Shang Y., Phelan M., Sif S., Myers M., Kingston R. et al. (2000) BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Mol. Cell Biol. 20: 7541-7549
39. Ito M., Yuan C. X., Malik S., Gu W., Fondell J. D., Yamamura S. et al. (1999) Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol. Cell 3: 361-370
40. Freedman L. P. (1999) Increasing the complexity of coactivation in nuclear receptor signaling. Cell 97: 5-8
41. Lanz R. B., McKenna N. J., Onate S. A., Albrecht U., Wong J., Tsai S. Y. et al. (1999) A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 97: 17-27
42. Nawaz Z., Lonard D. M., Smith C. L., Lev L., Tsai S. Y., Tsai M. J. et al. (1999) The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol. Cell Biol. 19: 1182-1189
43. Sivaraman L., Nawaz Z., Medina D., Conneely O. M. and O'Malley B. W. (2000) The dual function steroid receptor coactivator/ubiquitin protein-ligase integrator E6-AP is overexpressed in mouse mammary tumorigenesis. Breast Cancer Res. Treat. 62: 185-195
44. Mishra S. K., Mazumdar A., Vadlamudi R. K., Li F., Wang R. A., Yu W. et al. (2003) MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-α transactivation functions. J. Biol. Chem. 278: 19209-19219
45. Brunnberg S., Pettersson K., Rydin E., Matthews J., Hanberg A. and Pongratz I. (2003) The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription. Proc. Natl. Acad. Sci. USA 100: 6517-6522
46. Ohtake F., Takeyama K.-I., Matsumoto T., Kitagawa H., Yamamoto Y., Nohara K. et al. (2003) Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 423: 545-550
47. Vadlamudi R. K., Wang R. A., Mazumdar A., Kim Y., Shin J., Sahin A. et al. (2001) Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J. Biol. Chem. 276: 38272-38279
48. Balasenthil S. and Vadlamudi R. K. (2003) Functional interactions between the estrogen receptor coactivator PELP1 and retinoblastoma protein. J. Biol. Chem. 278: 22119-22127
49. Wang R. A., Mazumdar A., Vadlamudi R. K. and Kumar R. (2002) P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J. 21: 5437-5447
50. Lee S. R., Ramos S. M., Ko A., Masiello D., Swanson K. D., Lu M. L. et al. (2002) AR and ER interaction with a p21-activated kinase (PAK6). Mol. Endocrinol. 16: 85-99
51. Jepsen K. and Rosenfeld M. G. (2002) Biological roles and mechanistic actions of co-repressor complexes. J. Cell Sci. 115: 689-698
52. Huang H. J., Norris J. D. and McDonnell D. P. (2002) Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. Mol. Endocrinol. 16: 1778-1792
53. Shi Y., Downes M., Xie W., Kao H. Y., Ordentlich P., Tsai C. C. et al. (2001) Sharp, an inducible cofactor that integrates nuclear receptor repression and activation. Genes Dev. 15: 1140-1151
54. Delage M., Martini P. G., Choi I., Kraichely D. M., Hoeksema J. and Katzenellenbogen B. S. (2000) Analysis of estrogen receptor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA. J. Biol. Chem. 275: 35848-35856
55. Zhang H., Thomsen J. S., Johansson L., Gustafsson J. A. and Treuter E. (2000) DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors. J. Biol. Chem. 275: 39855-39859
56. Rajendran R. R., Nye A. C., Frasor J., Balsara R. D., Martini P. G. and Katzenellenbogen B. S. (2003) Regulation of nuclear receptor transcriptional activity by a novel DEAD box RNA helicase (DP97). J. Biol. Chem. 278: 4628-4638
57. Cheung E., Zarifyan A. S. and Kraus W. L. (2002) Histone H1 represses estrogen receptor alpha transcriptional activity by selectively inhibiting receptor-mediated transcription initiation. Mol. Cell Biol. 22: 2463-2471
58. Mazumdar A., Wang R. A., Mishra S. K., Adam L., Bagheri Y., Mandal M. et al. (2001) Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat. Cell Biol. 3: 30-37
59. Kumar R., Wang R. A., Mazumdar A., Talukder A. H., Mandal M., Yang Z. et al. (2002) A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418: 654-657
60. Talukder A. H., Mishra S. K., Mandal M., Balasenthil S., Mehta S., Sahin A. A. et al. (2003) MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions. J. Biol. Chem. 278: 11676-11685
61. Huang S. M. and Stallcup M. R. (2000) Mouse Zac1, a transcriptional coactivator and repressor for nuclear receptors. Mol. Cell Biol. 20: 1855-1867
62. Huang N., Vom B., Garnier J. M., Lerouge T., Vonesch J. L., Lutz Y. et al. (1998) Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO J. 17: 3398-3412
63. Sauve F., McBroom L. D., Gallant J., Moraitis A. N., Labrie F. and Giguere V. (2001) CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol. Cell Biol. 21: 343-353
64. Cavailles V., Dauvois S., Horset F., Lopez G., Hoare S., Kushner P. J. et al. (1995) Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 14: 3741-3751
65. Oesterreich S., Zhang Q., Hopp T., Fuqua S. A., Michaelis M., Zhao H. H. et al. (2000) Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol. Endocrinol. 14: 369-381
66. Lonard D. M. and Smith C. L. (2002) Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids 67: 15-24
67. Gajdos C. and Jordan V. C. (2002) Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade. Clin. Breast Cancer 2: 272-281
68. Murphy L. C. (1998) Mechanisms of hormone independence in human breast cancer. In Vivo 12: 95-106
69. Dorssers L. C. J., van der Flier S., Brinkman A., van Agthoven T., Veldscholte J., Berns E. M. J. J. et al. (2001) Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61: 1721-1733
70. Fuqua S. A. W., Schiff R., Parra I., Moore J. T., Mohsin S. K., Osborne C. K. et al. (2003) Estrogen receptor β protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 63: 2434
71. Speirs V. (2002) Oestrogen receptor beta in breast cancer: good, bad or still too early to tell? J. Pathol. 197: 143-147
72. Murphy L. C., Leygue E., Niu Y., Snell L., Ho S. M. and Watson P. H. (2002) Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br. J. Cancer 87: 1411-1416
73. Smith C. L., Nawaz Z. and O'Malley B. W. (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11: 657-666
74. Azorsa D. O., Cunliffe H. E. and Meltzer P. S. (2001) Association of steroid receptor coactivator AIB1 with estrogen receptor-alpha in breast cancer cells. Breast Cancer Res. Treat. 70: 89-101
75. Bautista S., Valles H., Walker R. L., Anzick S., Zeillinger R., Meltzer P. et al. (1998) In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin. Cancer Res. 4: 2925-2929
76. Reiter R., Wellstein A. and Riegel A. T. (2001) An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer. J. Biol. Chem. 276: 39736-39741
77. Kurebayashi J., Otsuki T., Kunisue H., Tanaka K., Yamamoto S. and Sonoo H. (2000) Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators and corepressors in breast cancer. Clin. Cancer Res. 6: 512-518
78. Girault I., Lerebours F., Amarir S., Tozlu S., Tubiana H., Lidereau R. et al. (2003) Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin. Cancer Res. 9: 1259-1266
79. Osborne C. K., Bardou V, Hopp T., Chamness G. C., Hilsenbeck S. G., Fuqua S. A. et al. (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 95: 353-361
80. Font de Mora J. and Brown M. (2000) AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell. Biol. 20: 5041-5047
81. Lauritsen K. J., List H. J., Reiter R., Wellstein A. and Riegel A. T. (2002) A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene 21: 7147-7155
82. Shang Y. and Brown M. (2002) Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468
83. Webb P., Nguyen P. and Kushner P. J. (2003) Differential SERM effects of corepressor binding dictate ERα activity in vivo. J. Biol. Chem. 278: 6912-6920
84. Behl C. (2002) Oestrogen as a neuroprotective hormone. Nat. Rev. Neurosci. 3: 433-442
85. Tang M. X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B. et al. (1996) Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348: 429-432
86. Kawas C., Resnick S., Morrison A., Brookmeyer R., Corrada M., Zonderman A. et al. (1997) A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 48: 1517-1521
87. Yaffe K., Sawaya G., Lieberburg I. and Grady D. (1998) Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279: 688-695
88. Zandi P. P., Carlson M. C., Plassman B. L., Welsh-Bohmer K. A., Mayer L. S., Steffens D. C. et al. (2002) Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 288: 2123-2129
89. Shumaker S. A. Legault C., Thai L., Wallace R. B., Ockene J. K., Hendrix S. L. et al. (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in post-menopausal women: the Women's Health Initiative Memory Study: A Randomized Controlled Trial. JAMA 289: 2651-2662
90. Rapp S. R. Espeland M. A., Shumaker S. A., Henderson V. W., Brunner R. L., Manson J. E. et al. (2003) Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: A Randomized Controlled Trial. JAMA 289: 2663-2672
91. Register T. C., Adams M. R., Golden D. L. and Clarkson T. B. (1998) Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterio. Thromb. Vasc. Biol. 18: 1164-1171
92. Jordan V. C. (2003) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor Interactions. J. Med. Chem. 46: 883-908
93. Jordan V. C. (2003) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J. Med. Chem. 46: 1081-1111
94. Cenci S., Weitzmann M. N., Roggia C., Namba N., Novack D. Woodring J. et al. (2000) Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α. J. Clin. Invest. 106: 1229-1237
95. Cenci S., Weitzmann M. N., Gentile M. A., Aisa M. C. and Pacifici R. (2000) M-CSF neutralization and Egr-1 deficiency prevent ovariectomy-induced bone loss. J. Clin. Invest. 105: 1279-1287
96. Toraldo G., Roggia C., Qian, W.-P., Pacifici R. and Weitzmann M. N. (2003) IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor κB ligand and tumor necrosis factor from T cells. Proc. Natl. Acad. Sci. USA 100: 125-130
97. Weitzmann M. N., Roggia C., Toraldo G., Weitzmann L. and Pacifici R. (2002) Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J. Clin. Invest. 110: 1643-1650
98. Ho K. J. and Liao J. K. (2002) Nonnuclear effects of estrogen. Arteriosclerosis Thrombosis Vasc. Biol. 22: 1952-1961
99. Ohmichi M., Kanda Y., Hisamoto K., Morishige K., Takahashi K., Sawada K. et al. (2003) Rapid changes of flow-mediated dilation after surgical menopause. Maturitas 44: 125-131
100. Simoncini T., Varone G., Fornari L., Mannella P., Luisi M., Labrie F. et al. (2002) Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth generation selective estrogen receptor modulator. Endocrinology 143: 2052-2061
101. Simoncini T., Fornari L., Mannella P., Varone G., Caruso A., Liao J. K. et al. (2002) Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase. Steroids 67: 935-939
102. Zhu W. and Smart E. J. (2003) Caveolae, estrogen and nitric oxide. Trends Endocrinol. Metabol. 14: 114-117
103. Ihionkhan C. E., Chambliss K. L., Gibson L. L., Hahner L. D., Mendelsohn M. E. and Shaul P. W. (2002) Estrogen causes dynamic alterations in endothelial estrogen receptor expression. Circ. Res. 91: 814-820
104. Dubey R. K., Gillespie D. G., Zacharia L. C., Barchiesi F., Imthurn B. and Jackson E. K. (2003) CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs. Hypertension 41: 807-813
105. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 288: 321-333
106. Wassertheil-Smoller S., Hendrix S. L., Limacher M., Heiss G., Kooperberg C., Baird A. et al. (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: A Randomized Trial. JAMA 289: 2673-2684
107. Snowdon D. A., Greiner L. H., Mortimer J. A., Riley K. P., Greiner P. A. and Markesbery W. R. (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277: 813-817
108. Simon T., Boutouyrie P., Simon J. M., Laloux B., Tournigand C., Tropeao A. I. et al. (2002) Influence of tamoxifen on carotid intima-media thickness in postmenopausal women. Circulation 106: 2925-2929
109. Wenger N. K., Barrett-Connor E., Collins P., Grady D., Kornitzer M., Mosca L. et al. (2002) Baseline characteristics of participants in the Raloxifene use for the heart (RUTH) trial. Am. J. Cardiol. 90: 1204-1210
110. Ceresini G., Marchini L., Rebecchi I., Morganti S., Bertone L., Montanari I. et al. (2003) Effects of raloxifene on carotid blood flow resistance and endothelium-dependent vasodilation in postmenopausal women. Athersclerosis 167: 121-127
111. Wallerath T., Deckert G., Ternes T., Anderson H., Li H., Witte K. et al. (2002) Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106: 1652-1658
112. Duffy S. J. and Vita J. A. (2003) Effects of phenolics on endothelial function. Curr. Opinion Lipidol. 14: 21-27